ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Regent Pacific Receives HK$24.96 million After Clinical Trial Approval For FORTACIN(TM) Has Been Obtained
April 02, 2021Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that the Group has received a payment of US$3.20 million (approximately HK$24.96 million) before deduction of PRC withholding ... -
Regent Pacific Announces Key Progresses On FORTACIN(TM) / SENSTEND(TM) - Solution to Premature Ejaculation
January 05, 2021Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce several key updates of Fortacin™ / Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on ...
Pharma Sources Insight January 2025
